Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2679 | Omega 3/Nigella Sativa Oil/Anise seed capsule Wiki | 0.45 |
| drug2682 | Omega 3/Nigella Sativa Oil/Quinine pills Wiki | 0.45 |
| drug976 | Collection of blood samples in order to create a biocollection Wiki | 0.45 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2680 | Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice Wiki | 0.45 |
| drug2681 | Omega 3/Nigella Sativa Oil/Indian Costus Wiki | 0.45 |
| drug2678 | Omega 3/Nigella Sativa Oil Wiki | 0.45 |
| drug202 | Active Comparator Wiki | 0.45 |
| drug1549 | Flow cytometric analysis Wiki | 0.32 |
| drug3192 | Questionnaire Wiki | 0.08 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D007153 | Immunologic Deficiency Syndromes NIH | 1.00 |
| D000077062 | Burnout, Psychological NIH | 0.11 |
| D004194 | Disease NIH | 0.07 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 5 clinical trials
CORIA is an observational cohort study of immunosuppressed populations who test positive for COVID-19. This includes people living with HIV, cancer, acquired immunodeficiency associated with other immunosuppressive therapy, primary immunodeficiency and recipients of a solid organ transplant. Participants will have routine clinical data collected with optional baseline collection and storage of a blood sample for storage . The study will be conducted in up to 30 sites within Australia.
A weekly questionnaire is sent to patients and parents of patients who are vulnerable for infections. Possible symptoms of COVID19 are asked for and use of healthcare services and testing for COVID19. Weekly reports are being send to the national institutions to update advice given to this group.
Description: To describe frequency of cough, fever, diarrhoea, shortness of breath, sore throat, blocked nose, red eyes, headache, joint pain, muscle pain, fatigue, chills, nausea, vomiting, diarrhoea over a year
Measure: To describe COVID19 infection in children/adults who are vulnerable for infection in an outpatients setting Time: 1 yearDescription: Patient/parent reported positive tests for COVID19
Measure: Number of children/adults tested positive for COVID19 Time: 1 yearDescription: Patient/parent reported admissions in hospital because of COVID19
Measure: Number of children/adults admitted in hospital because of COVID19 Time: 1 yearDescription: Patient/parent reported effect of COVID19 on daily activities
Measure: To assess the impact of COVID19 infection on the daily activities of immunosuppressed adults and children Time: 1 yearThe main objective of our project is to investigate the evolution of psychosocial, cardiovascular and immune markers in healthcare with different levels of exposure to the COVID-19 pandemic.
Description: Burnout - through self-reported stress and burnout thoughts, beliefs, emotions, behavior related to Covid-19 using Maslach Burnout Inventory. Maslach Burnout Inventory - is a 22-item survey that covers 3 areas: Emotional Exhaustion (EE), Depersonalization (DP), and low sense of Personal Accomplishment (PA). Each subscale includes multiple questions with frequency rating choices of Never, A few times a year or less, Once a month or less, A few times a month, Once a week, A few times a week, or Every day.
Measure: Change from Baseline Burnout at 2-3 months and 6 months Time: baseline, 2-3 months, 6 monthsDescription: Data is collected through wearable monitoring technology. Cardiovascular risk through monitoring of heart rate variability (HRV) markers. Changes of heart rate variability (HRV) reflecting cardiac autonomic dysfunction are associated with greater risks for cardiac morbidity and mortality.
Measure: Change from Baseline Cardiovascular Risk Cardiovascular Risk Through Heart Rate Variability Markers at 2-3 months and 6 months Time: baseline, 2-3 months, 6 monthsDescription: Data is collected through wearable monitoring technology. Actigraphy data is collected in 1 min epochs using the zero-crossing modes.
Measure: Change from Baseline Through Actigraphy at 2-3 months and 6 months Time: baseline, 2-3 months, 6 monthsDescription: Data is collected through wearable monitoring technology. Sleep efficiency is defined as the proportion of the estimated sleep periods spent asleep. Sleep latency is the length of time taken to fall asleep, calculated as the time between 'lights off' to the first period of 3 min of consecutive epochs scored as sleep.
Measure: Change from Baseline Through Sleep Quality at 2-3 months and 6 months Time: baseline, 2-3 months, 6 monthsDescription: Cardiovascular risk through Fuster-BEWAT score. The Fuster-BEWAT score will be analyzed as a continuous variable with total score ranging from 0 to 15 points. Additionally, each component will be categorized as ideal (3) or nonideal (0 to 2), and participants will be classified as having poor, intermediate, or ideal cardiovascular health based on the total number of ideal components (0 to 1 = poor, 2 to 3 = intermediate, 4 to 5 = ideal) (Fernández-Alvira et al., 2017).
Measure: Change from Baseline Cardiovascular Risk Through Fuster-BEWAT score at 2-3 months and 6 months Time: baseline, 2-3 months, 6 monthsDescription: Classification of the immune function will be screened.
Measure: Change from Baseline Immune Dysfunction at 2-3 months and 6 months Time: baseline, 2-3 months, 6 monthsDescription: Submaximal field test and maximal oxygen consumption (VO2, mL/kg/min).
Measure: Change from Baseline Cardio-Respiratory Fitness at 2-3 months and 6 months Time: baseline, 2-3 months, 6 monthsWith the emergence of SARS-CoV-2 and the COVID-19 pandemic, there is an urgent need to understand the impact of infection on immunodeficient individuals. Whilst co-morbidities (such as diabetes, cancer, arterial hypertension, heart disease...) have been documented in people infected with SARS-CoV-2, there is currently no information on the consequences and outcomes for individuals with primary immunodeficiencies (PID). Following the 1st phase of the survey (launched by Isabelle Meyts (ESID), Nizar Mahlaoui (CEREDIH & IPOPI) and Kate Sullivan with Stuart Tangye (IUIS), that gave an idea of the number of affected PID patients and the impact of SARS-CoV-2 and directly focusing on obtaining this top level of information), we are launching the 2nd phase: "COPID19". COPID19 survey is a secured online GDPR compliant platform based in Paris (Imagine Institute). It has been approved by the Paris-Necker-Enfants malades IRB and Ethics Committee. However, this retrospective survey is designed for global distribution. Data can be entered by a health care professional (mostly clinicians) through a personal login and password. Each documenting person will have access to his/her own patients' data. COPID19 require a greater level of information than the 1st phase. The eCRF will be open to evolutions depending on progresses in our knowledge of this pandemic.
The first version of this preprint article is registered on the 4th of May 2020 under the digital object identifier of:10.31219/osf.io/u56fc. COVID-19 infections virus spread worldwide and impact many countries with sever economical sequences. The effective antiviral medication or vaccination for the virus is unavailable until the present date and it takes months or years to discover the effective treatment or test the efficacy of the discovered treatment. Based on these facts, the human immune system against the virus may have an effective role to regulate the infection and reduce the mortality rate among the infected patients. This proposed research article aims to explore the available medication/ natural supplementation to boost the immunity system of the patients against COVID-19 infections and reduce the mortality rate among infected patients. Methods: a proposed clinical trial will be carried out to investigate the effect of the different treatment modalities on the human immune system against COVID-19 infection.
Description: Time to Clinical recovery
Measure: Clinical improvement Time: 30 DaysDescription: Percentage of patients returned to negative swaps of COVID-19
Measure: Recovery rate from positive to negative swaps Time: 14 DaysDescription: Number of days for fever remission T=37.5°C
Measure: Fever to normal temperature in days Time: 15 DaysDescription: Number of days to report lungs recovery in chest X ray or CT
Measure: Remission of lung inflammation in CT or X-ray Time: 30 DaysDescription: Number of days for hospitalization
Measure: Length of hospitalization Time: 10 DaysDescription: Change of (PCR levels) > 50% in comparison with PCR levels at the admission
Measure: (PCR levels) polymerase chain reaction assay levels Time: 10 DaysDescription: P O2/Fi O2 which reflects patients' oxygen saturation
Measure: Respiratory indexes Time: 10 DaysDescription: C-reactive protein milligrams per deciliter correlated with inflammation
Measure: C-reactive protein mg/L Time: 25 DaysDescription: Serum Ferritin Nanograms per milliliter correlated with iron overload and illness severity
Measure: Serum Ferritin ng/ml Time: 25 DaysDescription: Lactic acid dehydrogenase unit per litter correlated with illness severity
Measure: Lactic acid dehydrogenase U/L Time: 25 DaysDescription: leukocytes in microliter correlated with mortality
Measure: leukocytes count μl Time: 30 DaysDescription: Mg/dl correlated with lipid peroxidation that linked to oxidative stress
Measure: Lipid profile [LDL, HDL, Total cholesterol ] Time: 14 DaysDescription: Evaluate the antioxidant response against the free radicals produced in COVID-19 infection measured by ELISA
Measure: total plasma antioxidant capacity Time: 14 DaysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports